Live Analyst Rating Changes 16810 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Daniil Gataulin
CHAR

Daniil Gataulin

Chardan Capital
Wall Street Analyst
★★★☆☆
#1455
on 13Foresight · ranked by our own returns
41%
Success Rate
+6.5%
Average Return
9 of 22 calls profitable · +1.7% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 41% of Daniil Gataulin's ratings turned a profit when each position was held for 1 year — averaging +6.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

27 Buy 6 Hold 0 Sell
Daniil's Stock Coverage 18 ratings · 2026-07-31
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
OCUL
Ocular Therapeutix
 Jun 25, 2026 BUY Strong Buy
+192.9% avg upside
21 analysts
$23.00
175.04% Upside
 -16.4% ·
IRD
Opus Genetics
 Jun 17, 2026 BUY Strong Buy
+184.7% avg upside
25 analysts
$13.00
274.59% Upside
 +0.2% ·
CRVO
CervoMed
 May 17, 2026 BUY Strong Buy
+736.3% avg upside
9 analysts
$21.00
746.87% Upside
 -17.1% ·
MGTX
Meiragtx Holdings
 May 14, 2026 BUY Strong Buy
+119.1% avg upside
13 analysts
$35.00
201.22% Upside
 +16.2% ·
OCS
Oculis Holding
 May 12, 2026 BUY Strong Buy
+244.2% avg upside
11 analysts
$53.00
388.89% Upside
 -63.6% ·
KOD
Kodiak Sciences
 May 11, 2026 BUY Buy
+17.6% avg upside
11 analysts
$61.00
52.37% Upside
 +3.8% ·
FBRX
Forte Biosciences
 May 11, 2026 BUY Buy
-35.4% avg upside
15 analysts
$61.00
20.33% Downside
 +194.6% ·
CGTX
Cognition Therapeutics
 May 08, 2026 BUY Strong Buy
+541.2% avg upside
9 analysts
$4.00
343.92% Upside
 -21.6% ·
ZURA
Zura Bio
 May 07, 2026 BUY Strong Buy
+167.1% avg upside
13 analysts
$11.00
107.24% Upside
 +18.3% ·
OCGN
Ocugen
 May 07, 2026 BUY Strong Buy
+644.5% avg upside
17 analysts
$7.00
488.24% Upside
 -14.6% ·
EYPT
EyePoint Pharmaceuticals
 May 06, 2026 BUY Strong Buy
+162.3% avg upside
20 analysts
$29.00
143.22% Upside
 -1.1% ·
QURE
uniQure
 May 05, 2026 BUY Strong Buy
+42.3% avg upside
29 analysts
$37.00
7.73% Downside
 +105.9% ·
RGNX
RegenXBio
 Jan 28, 2026 BUY Strong Buy
+280.7% avg upside
22 analysts
$52.00
440.49% Upside
 -8.1% ·
OTLK
Outlook Therapeutics
 Jan 02, 2026 HOLD Buy
+789.8% avg upside
11 analysts
$1.00
0.04% Upside
 +51.5% ·
ANNX
Annexon Biosciences
 Dec 23, 2025 BUY Strong Buy
+175.5% avg upside
14 analysts
$16.00
229.30% Upside
 -0.8% ·
KLRS
Kalaris Therapeutics
 Dec 23, 2025 BUY Strong Buy
+269.5% avg upside
13 analysts
$19.00
458.84% Upside
 -64.3% ·
FR:SIGHT
GenSight Biologics SA
 Jun 13, 2025 HOLD Buy
+8962.7% avg upside
3 analysts
 — -63.0% ·
KRRO
Korro Bio
 Feb 15, 2023 HOLD Strong Buy
+160.9% avg upside
19 analysts
 — +59.9% ·
🔒 13 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Daniil Gataulin — Frequently Asked Questions
How accurate are Daniil Gataulin's stock ratings?
Based on the calls 13Foresight could measure, about 41% of Daniil's ratings were profitable over a one-year hold, with an average return of +7.2% per rating, or +28.8% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Daniil ranked on 13Foresight?
Daniil Gataulin is currently ranked #1455 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Daniil cover?
Daniil most recently has ratings on OCUL, IRD, CRVO, MGTX, OCS, KOD, FBRX, CGTX, ZURA, OCGN, EYPT, QURE and 6 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.